

#4
did
3/24/03

CERTIFICATE OF FACSIMILE TRANSMITTAL

Facsimile Number (703) 308-4242 Date of Transmission 3/25/03

I hereby certify that this correspondence (and all other documents mentioned therein) is being transmitted by facsimile to the Assistant Commissioner for Patents, Washington, D.C. 20231, to the above facsimile number on the above-date

Helena Beckman
Helena Beckman

FAX RECEIVED

MAR 26 2003

OFFICIAL GROUP 1600

Docket No. ONYX1034-CON1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventors: Paul Polakis, et al

SC/Serial No.:

10/053,422

Filed:

November 2, 2001

Title: Compositions and Methods for
Diagnosing/Treating Disease Based
on Beta-Catenin Transcription
Factor Interaction

PATENT APPLICATION

Examiner: Shin Lin CHEN

Art Unit 1632

Confirmation No. 7194

RESPONSE TO OFFICE ACTION UNDER 35 U.S.C. §121

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Responsive to the Office Action mailed February 27, 2003, setting forth a Restriction Requirement, Applicants elect without traverse, those claims in Group IV, Claims 6-8, drawn to a method of diagnosing for disease, classified in class 435, subclass 7.1.

Docket No. ONYX1034-CON1

Atty Docket ONYX1034-CON1
Serial No. 10/053,422

2

Although Applicants believe there are no fees due at this time, the Commissioner is hereby authorized to charge any fees associated with this communication to Deposit Account No. 15-0615.

Respectfully submitted,

Date: 3/25/03By: Gregory Giotta
Reg. No. 32,028

ONYX Pharmaceuticals, Inc.
3031 Research Drive
Richmond, California 94806
Telephone (510) 222-9700
Facsimile (510) 222-09758